Covalon Technologies Ltd. (COV.V)
CAD 3.44
(2.99%)
CAD 3.44
(2.99%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 24.9 Million CAD | -18.03% |
| 2022 | 30.37 Million CAD | -25.14% |
| 2021 | 40.58 Million CAD | 16.96% |
| 2020 | 34.69 Million CAD | -12.4% |
| 2019 | 39.6 Million CAD | 100.97% |
| 2018 | 19.7 Million CAD | 64.68% |
| 2017 | 11.96 Million CAD | 84.43% |
| 2016 | 6.48 Million CAD | -14.96% |
| 2015 | 7.63 Million CAD | -4.15% |
| 2014 | 7.96 Million CAD | 40.41% |
| 2013 | 5.67 Million CAD | -4.92% |
| 2012 | 5.96 Million CAD | -36.03% |
| 2011 | 9.32 Million CAD | -9.67% |
| 2010 | 10.31 Million CAD | -19.8% |
| 2009 | 12.86 Million CAD | -25.59% |
| 2008 | 17.29 Million CAD | -14.58% |
| 2007 | 20.24 Million CAD | 130.22% |
| 2006 | 8.79 Million CAD | 95.39% |
| 2005 | 4.5 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 26.52 Million CAD | 13.9% |
| 2024 Q2 | 23.28 Million CAD | 4.5% |
| 2024 Q1 | 22.28 Million CAD | -10.5% |
| 2023 Q1 | 30.01 Million CAD | -1.21% |
| 2023 Q2 | 27.92 Million CAD | -6.96% |
| 2023 Q3 | 26.44 Million CAD | -5.29% |
| 2023 FY | 24.9 Million CAD | -18.03% |
| 2023 Q4 | 24.9 Million CAD | -5.84% |
| 2022 FY | 30.37 Million CAD | -25.14% |
| 2022 Q2 | 34.56 Million CAD | -7.99% |
| 2022 Q3 | 32.02 Million CAD | -7.35% |
| 2022 Q1 | 37.56 Million CAD | -7.43% |
| 2022 Q4 | 30.37 Million CAD | -5.14% |
| 2021 Q4 | 40.58 Million CAD | 21.23% |
| 2021 Q1 | 32.15 Million CAD | -7.33% |
| 2021 Q2 | 33.19 Million CAD | 3.24% |
| 2021 Q3 | 33.47 Million CAD | 0.84% |
| 2021 FY | 40.58 Million CAD | 16.96% |
| 2020 Q3 | 38.39 Million CAD | -0.86% |
| 2020 Q2 | 38.72 Million CAD | -1.41% |
| 2020 FY | 34.69 Million CAD | -12.4% |
| 2020 Q1 | 39.27 Million CAD | -0.83% |
| 2020 Q4 | 34.69 Million CAD | -9.63% |
| 2019 Q3 | 34.11 Million CAD | -11.24% |
| 2019 FY | 39.6 Million CAD | 100.97% |
| 2019 Q2 | 38.43 Million CAD | 0.41% |
| 2019 Q1 | 38.28 Million CAD | 94.25% |
| 2019 Q4 | 39.6 Million CAD | 16.09% |
| 2018 Q3 | 16.18 Million CAD | 22.32% |
| 2018 Q1 | 13.04 Million CAD | 9.0% |
| 2018 FY | 19.7 Million CAD | 64.68% |
| 2018 Q4 | 19.7 Million CAD | 21.8% |
| 2018 Q2 | 13.22 Million CAD | 1.41% |
| 2017 Q1 | 7.02 Million CAD | 8.25% |
| 2017 FY | 11.96 Million CAD | 84.43% |
| 2017 Q4 | 11.96 Million CAD | 4.08% |
| 2017 Q3 | 11.49 Million CAD | 40.24% |
| 2017 Q2 | 8.19 Million CAD | 16.72% |
| 2016 Q3 | 7.65 Million CAD | -5.01% |
| 2016 Q2 | 8.06 Million CAD | -6.9% |
| 2016 Q4 | 6.48 Million CAD | -15.27% |
| 2016 FY | 6.48 Million CAD | -14.96% |
| 2016 Q1 | 8.65 Million CAD | 13.48% |
| 2015 Q1 | 8.01 Million CAD | 0.69% |
| 2015 Q4 | 7.63 Million CAD | -8.11% |
| 2015 FY | 7.63 Million CAD | -4.15% |
| 2015 Q2 | 8.53 Million CAD | 6.45% |
| 2015 Q3 | 8.3 Million CAD | -2.68% |
| 2014 FY | 7.96 Million CAD | 40.41% |
| 2014 Q1 | 9.19 Million CAD | 62.19% |
| 2014 Q3 | 9.17 Million CAD | -3.08% |
| 2014 Q4 | 7.96 Million CAD | -13.25% |
| 2014 Q2 | 9.46 Million CAD | 2.95% |
| 2013 Q1 | 5.3 Million CAD | -11.05% |
| 2013 Q4 | 5.67 Million CAD | 3.1% |
| 2013 FY | 5.67 Million CAD | -4.92% |
| 2013 Q3 | 5.49 Million CAD | 9.05% |
| 2013 Q2 | 5.04 Million CAD | -4.93% |
| 2012 Q3 | 7.34 Million CAD | -9.16% |
| 2012 Q2 | 8.09 Million CAD | -5.6% |
| 2012 Q1 | 8.56 Million CAD | -8.07% |
| 2012 FY | 5.96 Million CAD | -36.03% |
| 2012 Q4 | 5.96 Million CAD | -18.86% |
| 2011 FY | 9.32 Million CAD | -9.67% |
| 2011 Q4 | 9.32 Million CAD | 29.69% |
| 2011 Q3 | 7.18 Million CAD | -12.86% |
| 2011 Q2 | 8.24 Million CAD | -11.37% |
| 2011 Q1 | 9.3 Million CAD | -9.81% |
| 2010 Q3 | 11.53 Million CAD | 10.94% |
| 2010 Q4 | 10.31 Million CAD | -10.55% |
| 2010 FY | 10.31 Million CAD | -19.8% |
| 2010 Q1 | 12.38 Million CAD | -3.74% |
| 2010 Q2 | 10.39 Million CAD | -16.04% |
| 2009 Q4 | 12.86 Million CAD | -6.33% |
| 2009 Q3 | 13.73 Million CAD | -9.32% |
| 2009 Q2 | 15.14 Million CAD | -7.86% |
| 2009 Q1 | 16.44 Million CAD | -4.92% |
| 2009 FY | 12.86 Million CAD | -25.59% |
| 2008 Q2 | 18.72 Million CAD | -3.99% |
| 2008 Q4 | 17.29 Million CAD | -6.29% |
| 2008 Q3 | 18.45 Million CAD | -1.47% |
| 2008 FY | 17.29 Million CAD | -14.58% |
| 2008 Q1 | 19.5 Million CAD | -3.64% |
| 2007 Q3 | 11.41 Million CAD | 9.9% |
| 2007 FY | 20.24 Million CAD | 130.22% |
| 2007 Q1 | 8.55 Million CAD | -2.72% |
| 2007 Q4 | 20.24 Million CAD | 77.41% |
| 2007 Q2 | 10.38 Million CAD | 21.39% |
| 2006 Q3 | 9.32 Million CAD | -4.1% |
| 2006 Q2 | 9.72 Million CAD | 129.65% |
| 2006 Q1 | 4.23 Million CAD | -5.91% |
| 2006 Q4 | 8.79 Million CAD | -5.7% |
| 2006 FY | 8.79 Million CAD | 95.39% |
| 2005 FY | 4.5 Million CAD | 0.0% |
| 2005 Q1 | 4.29 Million CAD | 0.0% |
| 2005 Q2 | 4.95 Million CAD | 15.4% |
| 2005 Q4 | 4.5 Million CAD | -4.66% |
| 2005 Q3 | 4.72 Million CAD | -4.82% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.17 Million CAD | -2026.126% |
| Hemostemix Inc. | 313.76 Thousand CAD | -7836.065% |
| Universal Ibogaine Inc. | 6.31 Million CAD | -294.145% |
| Kane Biotech Inc. | 5.68 Million CAD | -338.32% |
| MedMira Inc. | 3.65 Million CAD | -581.871% |
| Marvel Biosciences Corp. | 672.38 Thousand CAD | -3603.302% |
| NervGen Pharma Corp. | 13.23 Million CAD | -88.127% |
| XORTX Therapeutics Inc. | 7.21 Million CAD | -245.359% |